Xeris Biopharma Holdings, Inc. SEC filings XERS
Xeris Biopharma Holdings, Inc. has 345 filings in SEC EDGAR's recent list, going back to Jul 2, 2021. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 21, 2026 | Apr 20, 2026 |
| S-8 | Employee stock plan registration | Mar 2, 2026 | — |
| 10-K | Annual report | Mar 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 2, 2026 | Mar 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 27, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 1, 2025 | Dec 1, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 3, 2025 | Jun 3, 2025 |
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 9, 2025 | — |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 23, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 28, 2025 | Mar 28, 2025 |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| S-8 | Employee stock plan registration | Mar 6, 2025 | — |
| S-3 | Shelf registration | Mar 6, 2025 | — |
| 10-K | Annual report | Mar 6, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2025 | Mar 6, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Results of operations
|
Jan 10, 2025 | Jan 10, 2025 |
| 10-Q | Quarterly report | Nov 8, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2024 | Nov 8, 2024 |
| UPLOAD | Letter from the SEC | Aug 13, 2024 | — |
| S-8 | Employee stock plan registration | Aug 8, 2024 | — |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| CORRESP | Letter to the SEC | Aug 6, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Aug 2, 2024 | Aug 1, 2024 |
| UPLOAD | Letter from the SEC | Jul 22, 2024 | — |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Jul 8, 2024 | Jul 7, 2024 |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 5, 2024 | Jun 5, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | Apr 23, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 5, 2024 |
| S-8 | Employee stock plan registration | Mar 6, 2024 | — |
| 10-K | Annual report | Mar 6, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Other events
|
Mar 6, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 4, 2024 | Jan 4, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 16, 2023 | Oct 16, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 29, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 27, 2023 | Sep 26, 2023 |
| 10-Q | Quarterly report | Aug 8, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 28, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 7, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| ARS | Annual report to shareholders | Apr 26, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 29, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Auditor change
|
Mar 17, 2023 | Mar 13, 2023 |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 10-K | Annual report | Mar 8, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Material agreement
|
Jan 20, 2023 | Jan 19, 2023 |
| 8-K |
Current report
Results of operations
|
Jan 5, 2023 | Jan 5, 2023 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 20, 2022 | Oct 20, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 3, 2022 | Sep 29, 2022 |
| 10-Q | Quarterly report | Aug 10, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2022 | Jun 8, 2022 |
| 424B5 | Prospectus supplement | May 11, 2022 | — |
| 10-Q | Quarterly report | May 11, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| DEFA14A | Additional proxy material | May 2, 2022 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Dec 31, 2021 |
| S-8 | Employee stock plan registration | Mar 11, 2022 | — |
| 10-K | Annual report | Mar 11, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Other events
|
Mar 10, 2022 | Mar 8, 2022 |
| 424B3 | Prospectus | Feb 8, 2022 | — |
| EFFECT | Filing | Feb 7, 2022 | — |
| EFFECT | Filing | Feb 7, 2022 | — |
| CORRESP | Letter to the SEC | Feb 4, 2022 | — |
| CORRESP | Letter to the SEC | Feb 4, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2022 | — |
| S-3 | Shelf registration | Jan 28, 2022 | — |
| S-3 | Shelf registration | Jan 28, 2022 | — |
| 8-K |
Current report
Other events
|
Jan 28, 2022 | Jan 28, 2022 |
| 8-K |
Current report
Results of operations
|
Jan 18, 2022 | Jan 18, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jan 3, 2022 | Jan 2, 2022 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Other events
|
Oct 8, 2021 | Oct 5, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 5, 2021 | Oct 5, 2021 |
| S-8 | Employee stock plan registration | Oct 5, 2021 | — |
| 8-K12B | Filing | Oct 5, 2021 | Oct 5, 2021 |
| 425 | Filing | Jul 30, 2021 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| 424B3 | Prospectus | Jul 29, 2021 | — |
| 425 | Filing | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 28, 2021 | — |
| S-4/A | Filing | Jul 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2021 | — |
| S-4 | Registration for a merger or exchange | Jul 2, 2021 | — |
Showing 129 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XERS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1867096
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.